Novo Nordisk teams with OpenAI

Novo Nordisk said Tuesday it is partnering with OpenAI to use artificial intelligence across drug discovery, manufacturing and commercial operations. (biospace.com) The Danish drugmaker said OpenAI’s tools will help its teams analyze large datasets, identify drug candidates and shorten the path from research to patient use. Novo said the rollout will span research and development, supply chains, distribution and internal business functions. (cnbc.com) Novo disclosed the partnership on April 14, 2026, but did not announce financial terms. The company said the arrangement includes data-governance rules and human oversight, and that it will also train employees to use the systems. (biospace.com) Drug discovery starts with a search problem: researchers sort through huge sets of biology and chemistry data to find molecules worth testing. Generative artificial intelligence systems can help by spotting patterns in that data and drafting candidate designs or workflows for scientists to review. (cnbc.com) Novo is making the move as competition in obesity and diabetes drugs has intensified. Reuters reported April 14 that Novo has fallen behind Eli Lilly in the weight-loss market, adding pressure to speed research and execution across the business. (usnews.com) The deal also lands in a pharmaceutical market that is spending more aggressively on artificial intelligence. Pharmaceutical Technology, citing GlobalData, reported that the total value of artificial-intelligence partnerships in pharma rose 120% year over year between 2024 and 2025. (pharmaceutical-technology.com) Novo had already been building out its artificial-intelligence stack before this announcement. Nvidia said on June 11, 2025, that it was collaborating with Novo Nordisk and the Danish Centre for AI Innovation to build custom models and agents for early research and clinical development using the Gefion supercomputer. (investor.nvidia.com) Chief executive Mike Doustdar said the OpenAI partnership is aimed at bringing “new and better treatment options” to patients faster. The test now is whether broader use of artificial intelligence can cut timelines inside a company that already dominates diabetes care and is fighting to regain momentum in obesity drugs. (cnbc.com)